AbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.
ADC manufacturer Heidelberg Pharma AG has negotiated a US$931m licensing and investment deal with China’s Huadong Medicine Co, Ltd.
The German inventor of alpha-amanitin antibody conjugates (ATACs) will receive an upfront payment of US$20m and milestone payments of up to US$449m related to its phase 1 multiple myeloma candidate HDP-101 and preclinical prostate cancer ATAC HDP-103, as well as royalties on sales of an undisclosed amount. However, the development partnership also covers two further candidates in early preclinical development as well as options on candidates yet to be generated, which are linked to milestone payments of a further USD 461 million. After a long period of waiting, Heidelberg Pharma has thus achieved a breakthrough in the partnering of Amanitin-coupled antibody technology.
In addition to in-licensing the pipeline, Huadong is taking a 35% or €105 million stake in Heidelberg Pharma, which is funded by dievini Holdung. Huadong will enroll Asian patients in global clinical trials to accelerate product development.
Paris-based Meletios Therapeutics SA has licenced know-how from the Institut Pasteur for the development of a new class of antivirals-
The European Circular Bioeconomy Fund has announced its final closing at €300m, €50m above its target.
TargED Biopharmaceuticals will use €39m from a Series A financing to bring its thrombolytic treatment to patients.
The cellular agriculture spin-off Onego Bio Ltd has been seeded with €10m to use its Trichoderma platform to establish an animal-free egg protein production.
The former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital has launched a new life sciences fund with initial capital commitments of €50m and a target size of €150m.